Patents Assigned to University of British Columbia
-
Publication number: 20250145721Abstract: Provided are humanized anti-HLA-A2 antibodies. In certain aspects, the humanized anti-HLA-A2 antibodies are capable of constituting an antigen binding domain of a chimeric antigen receptor (CAR), where the CAR is capable of being expressed in a human cell such that the CAR specifically binds to HLA-A2. Also provided are CARs that include the humanized anti-HLA-A2 antibodies. Modified cells including the antibodies and CARs, as well as methods of using such modified cells are also provided.Type: ApplicationFiled: June 21, 2024Publication date: May 8, 2025Applicants: The University of British Columbia, CDRD Ventures Inc.Inventors: Megan LEVINGS, Paul ORBAN, Nicholas DAWSON, Caroline LAMARCHE, Jan Peter BERGQVIST
-
Patent number: 12274686Abstract: This invention provides the use of specialized pro-resolving mediators (SPMs) for use as melanocyte growth promoters and pro-survival factors. More particularly, the SPM compositions are suitable for promoting melanocyte growth and/or survival to prevent depigmentation of melanocytes and/or promoting repigmentation in non-inflammatory depigmentation of melanocytes. Furthermore, the compositions may be used to treat dormant vitiligo lesions, chemically induced vitiligo, vitiligo that is non-responsive to inflammatory therapies, or canities.Type: GrantFiled: March 18, 2022Date of Patent: April 15, 2025Assignee: The University of British ColumbiaInventor: Youwen Zhou
-
Patent number: 12275779Abstract: The invention provides anti-14-3-3 eta antibodies that specifically bind to the human 14-3-3 eta protein isoform in its natural configuration while exhibiting selectivity over human 14-3-3 alpha, beta, delta, epsilon, gamma, tau, and zeta protein isoforms. Methods, kits and pharmaceutical compositions comprising said specific anti-14-3-3 eta antibodies are further provided for the diagnosis and treatment of arthritis.Type: GrantFiled: May 3, 2021Date of Patent: April 15, 2025Assignee: The University of British ColumbiaInventor: Anthony Marotta
-
Patent number: 12268878Abstract: A device and algorithm for controlling an autonomic function in an individual. A controller device that utilizes physiological measurements (such as blood pressure) to regulate spinal cord electrical stimulation to stabilize blood pressure. A control interface and algorithm for controlling an autonomic function in a subject. For instance, an algorithm that utilizes physiological measurements (such as blood pressure) to regulate spinal cord electrical stimulation to stabilize blood pressure.Type: GrantFiled: December 16, 2021Date of Patent: April 8, 2025Assignee: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Aaron Phillips, Andrei Krassioukov, Jordan Squair
-
Patent number: 12246076Abstract: There is provided peptidic compounds of Formula I, A or B(Rradn6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-?-Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or ?Me-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2 Thz, or Thz. ? represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9. Rradn6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.Type: GrantFiled: November 17, 2023Date of Patent: March 11, 2025Assignees: PROVINCIAL HEALTH SERVICES AUTHORITY, THE UNIVERSITY OF BRITISH COLUMBIAInventors: Kuo-Shyan Lin, François Bénard, Lei Wang, Zhengxing Zhang, Ivica Bratanovic, Chengcheng Zhang
-
Publication number: 20250073303Abstract: Disclosed is a peptide including (a) a cell membrane penetration (CMP) sequence; and (b) one or more TDP-43 phosphorylation-blocking (PB) sequences. Also disclosed is a method of reducing the phosphorylation of TDP-43 in a cell, the method including: delivering an effective amount of a peptide to the cell, wherein the peptide comprises: (a) a cell membrane penetration (CMP) sequence; and (b) a TDP-43 phosphorylation-blocking (PB) sequence. Also disclosed is a method of treating a disease or pathological condition, the method comprising administering an effective amount of a peptide to a subject in need thereof; wherein the peptide comprises: (a) a cell membrane penetration (CMP) sequence; and (b) one or more TDP-43 phosphorylation-blocking (PB) sequences. Related uses, peptides for use, vectors, polynucleotide, and pharmaceutical compositions are disclosed.Type: ApplicationFiled: January 6, 2023Publication date: March 6, 2025Applicant: The University of British ColumbiaInventors: Jingyan Zhu, Max Cynader
-
Patent number: 12233416Abstract: Limit size lipid nanoparticles, methods for using the lipid nanoparticles, and methods and systems for making limit size lipid nanoparticles.Type: GrantFiled: April 6, 2023Date of Patent: February 25, 2025Assignee: The University of British ColumbiaInventors: Pieter R. Cullis, Igor V. Jigaltsev, Robert James Taylor, Timothy Leaver, Andre Wild, Nathan Maurice Belliveau
-
Publication number: 20250059499Abstract: Provided herein are compounds including a linear polyglycerol, a peptide tag, with either a linker-sugar-sialic acid moiety or a sulfate group, a preservation solutions including the compounds, methods for using the compounds or the preservation solutions to cell surface engineering (CSE) of a cell, a tissue, an organ for transplant, and methods for making the compounds. In particular, the CSE may recapitulate or rebuild glycocalyx on the luminal endothelial surface of an organ to limit immune rejection of the organ after transplant.Type: ApplicationFiled: June 22, 2022Publication date: February 20, 2025Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, SIMON FRASER UNIVERSITYInventors: Jayachandran N. KIZHAKKEDATHU, Erika M.J. SIREN, Jonathan C. CHOY, Haiming D. LUO, Stephen G. WITHERS, Caigan DU, Winnie ENNS
-
Patent number: 12226520Abstract: A simple, self-propelling particle system is disclosed that can deliver a cargo through flowing aqueous solutions. This disclosure provides a non-aqueous composition comprising: (i) particles formed of a carbonate salt and having an average diameter of about 100 ?m or less; and (ii) an acid in solid form. The particles may be associated with a cargo molecule or particle. In mouse models of severe hemorrhage, the propelled particles are able to deliver a procoagulant enzyme and halt bleeding.Type: GrantFiled: March 4, 2022Date of Patent: February 18, 2025Assignees: The University of British Columbia, The General Hospital CorporationInventors: Christian Kastrup, Ju Hun Yeon, James Baylis, Thomas Frederick Burke
-
Patent number: 12201597Abstract: This invention provides the use of specialized pro-resolving mediators (SPMs) for use as melanocyte growth promoters and pro-survival factors. More particularly, the SPM compositions are suitable for promoting melanocyte growth and/or survival to prevent depigmentation of melanocytes and/or promoting repigmentation in non-inflammatory depigmentation of melanocytes. Furthermore, the compositions may be used to treat dormant vitiligo lesions, chemically induced vitiligo, vitiligo that is non-responsive to inflammatory therapies, or canities.Type: GrantFiled: March 18, 2022Date of Patent: January 21, 2025Assignee: The University of British ColumbiaInventor: Youwen Zhou
-
Patent number: 12199398Abstract: Methods, circuits, and techniques for reflection cancellation. Laser output is tapped. A tapped portion of the laser output is phase shifted to generate a feedback signal, with the feedback signal being out-of-phase with a parasitic reflection of the laser output. The feedback signal is directed towards the laser such that the parasitic reflection and feedback signal are superpositioned before entering the laser. A magnitude and a phase of the feedback signal are such that superposition of the feedback signal and the parasitic reflection results in a resulting signal of lower magnitude than the parasitic reflection alone. During laser operation, a magnitude of the resulting signal is monitored and, as the parasitic reflection varies, the magnitude of the resulting signal is adjusted by adjusting at least one of the magnitude and the phase of the feedback signal in response to the monitoring of the resulting signal.Type: GrantFiled: June 18, 2021Date of Patent: January 14, 2025Assignee: The University of British ColumbiaInventors: Lukas Chrostowski, Nicolas A. F. Jaeger, Sudip Shekhar, Hasitha Jayatilleka, Hossam A. S. Shoman
-
Patent number: 12186724Abstract: A method for transporting a material (which may be a viscous fluid) in a conduit defined by a conduit-defining surface comprises: flowing a first fluid and a second fluid in a flow direction within the conduit; contacting the first and second fluids to one another at a contact region to thereby facilitate a reaction creating a reaction product in an interface region that extends downstream from the contact region, wherein the reaction product is an elastic-solid; and transporting the material in the flow direction within the conduit. At locations downstream of interface region, the reaction product creates a barrier between the viscous fluid and the conduit-defining surface.Type: GrantFiled: May 2, 2024Date of Patent: January 7, 2025Assignee: The University of British ColumbiaInventors: Jordan Mackenzie, Dominic Mark Martinez, Sean Matthew Delfel, Michael Buchen, Rami Younes
-
Patent number: 12173055Abstract: The disclosure pertains to N-terminal epitopes identified in A-beta, including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.Type: GrantFiled: September 8, 2020Date of Patent: December 24, 2024Assignee: The University of British ColumbiaInventors: Neil R. Cashman, Steven S. Plotkin
-
Patent number: 12171833Abstract: This invention provides compositions for controlled localized depositing of one or more drugs within a subject. More particularly, described herein are compositions comprising a) a polyethylene glycol (PEG) composition having a first low molecular weight PEG (Mw between 200-500 Da) and a second low molecular weight PEG (Mw between 500-2000 Da) and b) a mucoadhesive in polymer. Alternatively, composition may comprise a) a polyethylene glycol (PEG) composition having a first low molecular weight PEG (Mw between 200-500 Da) and a second low molecular weight PEG (Mw between 500-2000 Da), b) a water insoluble polymer and c) a mucoadhesive polymer. Furthermore, the composition may further comprise one or more drugs. Also provided are methods of manufacturing and administering the compositions described herein, which are used as biodegradable, injectable mucoadhesive low-viscosity pastes.Type: GrantFiled: February 6, 2021Date of Patent: December 24, 2024Assignee: The University of British ColumbiaInventors: Veronika Schmitt, John K. Jackson, Martin E. Gleave, Claudia Kesch
-
Patent number: 12167877Abstract: Implantable devices for fixation of curved bone such as the pelvic ring pubic symphysis and acetabulum, and methods for the use of the devices are disclosed. The implantable devices are convertible between a flexible state and a rigid state, and include an elongate structure having a proximal bone interface, a main body, and a distal bone interface. In a flexible state, the devices may be inserted along, and conform to a curved pathway, and in the rigid state, the devices may support the mechanical loads required to fixate a fracture.Type: GrantFiled: May 17, 2022Date of Patent: December 17, 2024Assignees: The University of British Columbia, British Columbia Cancer Agency BranchInventors: Edward Scott Harshman, Steven Charles Dimmer, Daniel Reed Baker, David Thomas Stinson, Robert N. Meek, Robin John Noel Coope, Lok Tin Lam
-
Publication number: 20240374754Abstract: The present disclosure provides a lipid nanoparticle comprising encapsulated mRNA and at least 30 mol % of a sphingolipid (e.g. sphingomyelin (SM)), and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticle comprising a core comprising an electron dense region and an aqueous portion surrounded at least partially by a lipid layer comprising a bilayer and the lipid nanoparticle exhibiting at least a 2-fold increase in gene expression in the liver, spleen and/or bone marrow at 4 or 24 hours post-injection as compared to a lipid nanoparticle encapsulating mRNA with an Onpattro™-type formulation of cationic, ionizable lipid/DSPC or ESM/cholesterol/PEG-lipid at 50/10/38.5/1.5, mol:mol, wherein the gene expression is measured in an animal model by detection of green fluorescent protein (GFP). Further provided are methods of medical treatment and uses of such lipid nanoparticles to treat or prevent a disease condition in a hepatic or non-hepatic tissue or organ.Type: ApplicationFiled: May 31, 2022Publication date: November 14, 2024Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Jayesh A. KULKARNI, Nisha CHANDER, Genc BASHA, Marco A. CIUFOLINI, Dominik WITZIGMANN, Pieter R. CULLIS
-
Patent number: 12134572Abstract: A UV reactor irradiates a flow of fluid with UV radiation. The reactor comprises: a fluid conduit defined by a heat conducting conduit body comprising one or more heat conducting walls for permitting a flow of fluid therethrough; a UV-LED operatively connected to a PCB and oriented for directing radiation into the fluid conduit. The PCB comprises a heat conducting substrate having a first surface. The conduit body is in thermal contact with the first surface of the heat conducting substrate. Heat is dissipated from the UV-LED via the heat conducting substrate, the thermal contact between the first surface of the heat conducting substrate and the heat conducting conduit body, and from the one or more heat conducting walls of the heat conducting conduit body to the fluid flowing through the fluid conduit.Type: GrantFiled: May 15, 2023Date of Patent: November 5, 2024Assignee: THE UNIVERSITY OF BRITISH COLUMBIAInventor: Fariborz Taghipour
-
Patent number: 12126100Abstract: An electromagnetic wave manipulation apparatus may include a substrate integrated with a liquid crystal. For example, the substrate may include one or more cavities filled with the liquid crystal. Alternatively and/or additionally, the substrate may include one or more layers of material interposed with the liquid crystal. The liquid crystal may be subjected to a voltage bias that alters the dielectric constant of the liquid crystal. Doing so may introduce a corresponding field offset between the input signal and the output signal of the apparatus. Subjecting the liquid crystal to different voltage biases may give rise to a spatial phase gradient that enables the apparatus to perform a variety of electromagnetic wave transformations such as reflection, refraction, retro-reflection, amplification, and cancellation. By performing such transformations, the apparatus may change the radiation pattern of its output signal, thus steering its output signal towards or away from a receiver.Type: GrantFiled: September 29, 2021Date of Patent: October 22, 2024Assignees: The Regents of the University of California, The University of British ColumbiaInventors: Sudip Shekhar, Md Nazmul Hasan, Dinesh Bharadia
-
Patent number: 12117354Abstract: A pair of first electrodes 111, 112 is arranged in a state being separated in a direction parallel to a contact surface 102 of a base material 10 made of a dielectric and being at least partially in contact with the base material 10. A pair of second electrodes 121, 122 is arranged in a state of overlapping at least one of the pair of first electrodes and sandwiching the base material 10 at a position farther from the contact surface 102 of the base material 10 than the pair of first electrodes 111 and 112 in a direction perpendicular to the contact surface 102 of the base material 10. The proximity state of an object Q with respect to the contact surface 102 of the base material 10 is detected according to the measurement result of the capacitance C1 between the pair of first electrodes 111 and 112.Type: GrantFiled: July 28, 2020Date of Patent: October 15, 2024Assignees: Honda Motor Co., Ltd, The University of British ColumbiaInventors: Ryusuke Ishizaki, John D. W. Madden, Mirza S. Sarwar, Yuta Dobashi
-
Publication number: 20240335803Abstract: The present disclosure is directed towards improved systems and methods for large-scale production of nanoparticles used for delivery of therapeutic material. The apparatus can be used to manufacture a wide array of nanoparticles containing therapeutic material including, but not limited to, lipid nanoparticles and polymer nanoparticles. In certain embodiments, continuous flow operation and parallelization of microfluidic mixers contribute to increased nanoparticle production volume.Type: ApplicationFiled: February 6, 2024Publication date: October 10, 2024Applicant: The University of British ColumbiaInventors: Euan Ramsay, Robert James Taylor, Timothy Leaver, Andre Wild, Kevin Ou, Colin Walsh